Martin Shkreli is expected to speak at Harvard on Wednesday amid a pending federal court case on security fraud charges.
A Brooklyn federal judge gave Shkreli the “OK” to travel to Harvard University to speak, according to the New York Post.
The approval came after Shkreli wrote a letter to the judge asking for permission to travel to Harvard for the speaking engagement.
The former CEO of Turing Pharmaceuticals has been accused of “conducting an $11 million Ponzi scheme,” which has prompted some to refer to him as the “Most Hated Man in America,” along with the nickname "Pharma bro," the Post noted.
According to The Associated Press, Shkreli’s company marked up the price on a drug that was seen as a potential life-saver for HIV patients from less than $17 to $750 per pill.
Shkreli is currently out on $5 million bail in an unrelated case in which he is accused of conducting an $11 million Ponzi scheme, the Post reported.
As a result, he’s required to gain court approval when planning to travel outside of New York City.
This isn’t the first time Shkreli has asked for approval to travel for a speaking engagement. He previously was allowed to travel to the University of California, Davis, to speak at an event, and he was given permission to travel to the nation’s capital last month for President Donald Trump’s inauguration.
The Harvard speaking engagement, which is scheduled for Wednesday at 8:30 p.m. and organized by the Harvard Financial Analysts Club, will be open to the school’s community, according to The Associated Press.
Shkreli will be discussing investments and health care during the talk.
The Harvard Financial Analysts Club, which is hosting the event, has asked those who plan on attending to show Shkreli respect during his visit, according to Mass Live.
“If you disagree with Mr. Shkreli or his policies, we celebrate your right to do so,” club members wrote on a Facebook page for the event. “We only ask that you express your grievances with respect for your fellow peers and through the appropriate channels (e.g. the Q&A).”
© 2025 Newsmax. All rights reserved.